Type-II kinase inhibitors that target Parkinson's Disease-associated LRRK2.
Raig ND, Surridge KJ, Sanz-Murillo M, Dederer V, Krämer A, Schwalm MP, Elson L, Chatterjee D, Mathea S, Hanke T, Leschziner AE, Reck-Peterson SL, Knapp S.
Raig ND, et al. Among authors: chatterjee d.
bioRxiv [Preprint]. 2024 Oct 31:2024.09.17.613365. doi: 10.1101/2024.09.17.613365.
bioRxiv. 2024.
PMID: 39554022
Free PMC article.
Preprint.